Oppenheimer reiterates Amgen stock rating on cancer drug data
In
Investing.comBy Investing.com10/25/2026, 11:20:51 PM
EXECUTIVE SUMMARY
Oppenheimer reiterates Amgen stock rating on cancer drug data....
Key Takeaways
- Oppenheimer reiterates Amgen stock rating on cancer drug data.
Read Complete Original Article
Published originally on Investing.com
Related News
finance43 minutes ago
Horizon Kinetics buys Texas Pacific Land stock for $340
Horizon Kinetics buys Texas Pacific Land stock for $340....
finance1 hour ago
Apple seeks more iPhone Duo supplies amid strong demand for debut foldable- report
Apple seeks more iPhone Duo supplies amid strong demand for debut foldable- report....
finance1 hour ago
Oil prices down almost $1 in early trading
Oil prices down almost $1 in early trading....
finance1 hour ago
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data....
Multikhabar App
All Information In One Place
Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!